Literature DB >> 9141524

High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.

H M Behre1, S Kliesch, G Pühse, T Reissmann, E Nieschlag.   

Abstract

The GnRH antagonist cetrorelix effectively suppresses serum LH, FSH, and testosterone (T) in normal men without major side-effects. However, as with other available GnRH antagonists, relatively high doses of 10 mg/day were required for sustained reduction of T levels during 1-week administration in normal men. Therefore, we investigated whether a suppression of LH, FSH, and T achieved by initial high dose cetrorelix can be maintained by continued low dose injections. Sixteen young male volunteers were randomly assigned to four study groups (n = 4/group). Twelve men were injected s.c. with 10 mg cetrorelix at 0800 h for 5 days, followed by injections of 2 mg/day (group I), 2 x 1 mg/day (group II), and 1 mg/day (group III) up to the end of the 3-week injection period. For the control, group IV was given daily placebo injections for 3 weeks. Morning and evening blood samples were obtained daily for 4 weeks and then at increasing time intervals up to week 13. Initial injections of 10 mg/day cetrorelix suppressed LH, FSH, and T effectively. This initial reduction of serum levels was maintained during the following low dose maintenance injections in all groups. In comparison to the initial suppression, significantly lower levels of LH, FSH, and T near the assay detection limits were measured during study weeks 2 and 3. The results show that compared to previous long term studies, much lower daily doses of the GnRH antagonist are sufficient for effective suppression of LH, FSH, and T after initial high loading dose injections. In addition to competitive receptor blockage, other mechanisms of GnRH antagonist action, such as receptor down-regulation, appear to be involved during long term administration in men.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141524     DOI: 10.1210/jcem.82.5.3959

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.

Authors:  Judit E Horvath; Ana M Bajo; Andrew V Schally; Magdolna Kovacs; Francine Herbert; Kate Groot
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

Review 2.  Continuing the search for a hormonal male contraceptive.

Authors:  Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-02-19       Impact factor: 5.237

3.  Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

Authors:  David B MacLean; Hongliang Shi; Hélène M Faessel; Fred Saad
Journal:  J Clin Endocrinol Metab       Date:  2015-10-26       Impact factor: 5.958

4.  Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.

Authors:  Judit E Horvath; Gabor L Toller; Andrew V Schally; Ana-Maria Bajo; Kate Groot
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

5.  Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial.

Authors:  J P Dias; D Melvin; E M Simonsick; O Carlson; M D Shardell; L Ferrucci; C W Chia; S Basaria; J M Egan
Journal:  Andrology       Date:  2015-11-20       Impact factor: 3.842

6.  Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH.

Authors:  M Kovacs; A V Schally; B Csernus; Z Rekasi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.